292
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

G-CSF improves safety when you start the day after autologous transplant in multiple myeloma

, , , , , , , , , , , & show all
Pages 2947-2951 | Received 03 Nov 2016, Accepted 05 Apr 2017, Published online: 16 May 2017

References

  • Attal M, Lauwers-Cances V, Hulin C, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood. 2015;126:391–391.
  • Klumpp TR, Mangan KF, Goldberg SL, et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. JCO. 1995;13:1323–1327.
  • Schmitz N, Ljungman P, Cordonnier C, et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant. 2004;34:955–962.
  • Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update. JCO. 2015;33:3199–3212.
  • de Azevedo AM, Nucci M, Maiolino A, et al. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant. 2002;29:745–751.
  • Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–560.
  • Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656–664.
  • Valteau-Couanet D, Faucher C, Auperin A, et al. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant. 2005;36:547–552.
  • Cox JE, Campos S, Wu J, et al. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014;49:219–222.
  • Gertz MA, Gastineau DA, Lacy MQ, et al. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplant. 2011;46:956–961.
  • Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 2000;110:292–299.
  • Cho YK, Sborov DW, Lamprecht M, et al. Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clin Pharmacol Ther. Forthcoming 2017. [Feb 4]. DOI:10.1002/cpt.644
  • Herbert K, Ritchie DS. The Goldilocks conundrum: how much granulocyte colony-stimulating factor following autologous stem cell transplant is ‘just right’? Leuk Lymphoma. 2011;52:548–549.
  • Khot A, Dickinson M, Stokes K, et al. A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013;13:42–47.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.